Search results for "reduced"

showing 10 items of 191 documents

A clinical diagnosis of oral leukoplakia: A guide for dentists

2017

Background In view of the many white or predominantly white lesions of the oral mucosa it is a challenge for dentists to clinically identify a leukoplakia, being a potentially (pre)malignant lesion. Material and Methods Based on the available literature and experience of the authors the parameters of a clinical diagnosis of oral leukoplakia have been studied. Results A guide has been presented that should help dentists to establish a clinical diagnosis of leukoplakia as accurate as possible. Conclusions Probably in most parts of the world dentists will need the help of a specialist for confirmation or exclusion of the clinical diagnosis of oral leukoplakia and for further management of the …

medicine.medical_specialtyMEDLINEReview03 medical and health sciences0302 clinical medicinestomatognathic systemPatient informationmedicineHumansOral DiagnosisOral mucosaGeneral DentistryLeukoplakiaOral Medicine and Pathologybusiness.industry030206 dentistryBenign lesionSDG 10 - Reduced Inequalities:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologyOral leukoplakiastomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyDentistry030220 oncology & carcinogenesisClinical diagnosisPractice Guidelines as TopicUNESCO::CIENCIAS MÉDICAS/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalitiesSurgeryLeukoplakia Oralbusiness
researchProduct

Platelet Phenotyping and Function Testing in Thrombocytopenia.

2021

Patients who suffer from inherited or acquired thrombocytopenia can be also affected by platelet function defects, which potentially increase the risk of severe and life-threatening bleeding complications. A plethora of tests and assays for platelet phenotyping and function analysis are available, which are, in part, feasible in clinical practice due to adequate point-of-care qualities. However, most of them are time-consuming, require experienced and skilled personnel for platelet handling and processing, and are therefore well-established only in specialized laboratories. This review summarizes major indications, methods/assays for platelet phenotyping, and in vitro function testing in bl…

medicine.medical_specialtyPlatelet disorderlcsh:MedicinethrombocytopeniaReview030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineplatelet function testsmedicineplatelet disordersPlateletAcquired thrombocytopeniaIntensive care medicineReduced platelet countbusiness.industryflow cytometrylcsh:RGeneral Medicineplatelet countbleedingClinical PracticeFunction analysisPlatelet function testbusiness030215 immunologyJournal of clinical medicine
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Hyaluronic Acid in the Treatment of Pain Due to Knee Joint Immobilisation

1995

This open, randomised study was carried out in order to evaluate the safety and efficacy of a course of 5 intra-articular injections (one per week) of hyaluronic acid (HA), administered to patients with pain and joint stiffness resulting from immobilisation of the knee in a plaster cast. The study was made in comparison with an untreated control group. 30 patients of both genders, aged between 18 and 65 years, immobilised in a plaster cast for at least 20 days and presenting with pain and reduced mobility, were included in the study. The results of the study show that, in comparison with the control group, treatment with HA produced a more rapid and effective reduction in pain and increase …

medicine.medical_specialtybusiness.industrySignificant differenceReduced mobilityGeneral MedicineKnee JointSurgerychemistry.chemical_compoundchemistryJoint mobilityUntreated controlJoint stiffnessHyaluronic acidmedicinePharmacology (medical)medicine.symptomAdverse effectbusinessClinical Drug Investigation
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

Preemptive analgesia in dental implant surgery: A systematic review and meta-analysis of randomized controlled trials

2021

Background To assess the effectiveness of preemptive analgesia in dental implant surgery in randomized controlled trials (RCTs). Material and Methods The present study was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and registered in PROSPERO database CRD42020168757. A search without restrictions regarding language or date of publication was conducted in six databases and gray literature. A random effect meta-analysis compared the efficacy of preemptive analgesia compared to placebo through pooled OR and 95%CI. The interpretation of results followed the certainty of evidence using the Grading of Rec…

medicine.medical_specialtymyeloablative conditioningMEDLINEReviewacute myeloid leukemiaPlaceboMean differencelaw.inventionDental implant surgeryRandomized controlled triallawmedicineHumansxerostomiaGeneral DentistryUNESCO:CIENCIAS MÉDICASRandomized Controlled Trials as TopicDental Implantsbusiness.industryRandom effects modelSystematic reviewOtorhinolaryngologyMeta-analysisPhysical therapySurgeryAnalgesiaoral pathologybusinessImplantologyreduced-intensity conditioningMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Quelques observations récentes sur des sites de l'Antiquité tardive à Autun (2001-2008)

2011

This article describes the result of ten or so fairly limited preventive archaeology operations (surveillance of works, diagnostics not followed up with excavations) carried out over the last ten years that have nonetheless finalised knowledge of several deposits from Late Antiquity in Autun located intra muros but also outside the walls. The works have enabled us to renew our knowledge of the reduced enclosure and of three Late Antiquity necropolises, to discover the remains of a lime kiln from the end of the 4th century at the centre of a public zone (perhaps the forum), and lastly to point up the difficulties of interpretation of an occupation of two zones from the end of the 4th century…

monumental zonelime kiln[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and PrehistoryReduced enclosuredomusîlot monumental[ SHS.ARCHEO ] Humanities and Social Sciences/Archaeology and PrehistoryEnceinte réduiteforumatelier de chaufourniernécropolenecropolis
researchProduct

Photocatalytic H2 evolution from aqueous solutions of oxygenated organic compounds in the presence of C3N4/reduced graphene oxide based photocatalysts

2022

Composites of C3N4/reduced graphene oxide have been used as a cheap and promising photocatalysts for triethanolamine and ethanol photo-reforming with H2 generation in aqueous solution. The rate of H2 production over the best performing photocatalysts reached 1,415 μmol·h-1·g-1 which increases up to 57,306 in the presence of 1% of Pt. The apparent quantum efficiency of the optimal material was 7 % by using both LED and natural sunlight irradiation

photoreformingH2 generationphotocatalysisreduced graphene oxideC3N4
researchProduct